Mineralys Therapeutics, Inc. (MLYS) has a consensus analyst rating of Buy, based on 8 analysts covering the stock. Of those, 7 recommend buying, 1 recommend holding, and 0 recommend selling.
The analyst consensus price target for MLYS is $46.00, representing a +68.4% upside from the current price of $27.32. Price targets range from a low of $30.00 to a high of $56.00.
